Kari Kendra, MD, PhD, The Ohio State University, Columbus, OH, comments on the optimal order of treatment for patients with metastatic melanoma. Based on findings from the DREAMseq trial (NCT02224781), immunotherapy is the preferred therapy of choice in the first line setting, where combination therapies such as relatlimab with nivolumab are chosen. However, monotherapy strategies are still considered for a small number of patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.